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ABSTRACT:  34 
WNT ligands can activate several signalling cascades of pivotal importance during 35 
development and regenerative processes. Their de-regulation has been associated with the 36 
onset of different diseases. Here we investigated the role of the Wnt/Calcium Calmodulin 37 
Kinase II (CaMKII) pathway in osteoarthritis. We identified Heme Oxygenase I (HMOX-1) and 38 
Sox-9 as specific markers of the WNT/CaMKII signalling in articular chondrocytes through a 39 
microarray analysis. We showed that the expression of the activated form of CaMKII, phospho-40 
CaMKII, was increased in human and murine osteoarthritis and the expression of HMOX-1 41 
was accordingly reduced, demonstrating the activation of the pathway during disease 42 
progression. To elucidate its function, we administered the CaMKII inhibitor KN93 to mice in 43 
which osteoarthritis was induced by resection of the anterior horn of the medial meniscus and 44 
of the medial collateral ligament in the knee joint. Pharmacological blockade of CaMKII 45 
exacerbated cartilage damage and bone remodelling. Finally, we showed that CaMKII 46 
inhibition in articular chondrocytes upregulated the expression of matrix remodelling enzymes 47 
alone and in combination with Interleukin 1. These results suggest an important homeostatic 48 
role of the WNT/CaMKII signalling in osteoarthritis which could be exploited in the future for 49 
therapeutic purposes. 50 















Osteoarthritis (OA) is a joint disease driven by pathological biomechanics and characterized 64 
by cartilage breakdown, subchondral bone sclerosis, osteophytosis, and inconstant low 65 
degree inflammation1. OA is a leading cause of chronic disability worldwide: patients suffer 66 
from joint pain and impaired motility, which reduces their independence 2. No therapeutic 67 
treatment other than symptomatic relief is currently available, leaving joint replacement 68 
surgery as the ultimate option.  69 
OA progression is driven by an imbalance between cartilage degradation and reparative, 70 
homeostatic responses. Pathological biomechanical stimuli activate signalling pathways 71 
including interleukin 1 beta (IL1B)3 and the WNT pathway4, which in turn upregulate matrix 72 
metalloproteases (MMPs) and A Disintegrin and Metalloproteinase with Thrombospondin 73 
motifs (ADAMTS) aggrecanases, which contribute to the degradation of the cartilage 74 
extracellular matrix5. 75 
Excessive activation of the WNT signalling pathway has been linked to the onset and 76 
progression of cartilage degeneration in OA, both in human and in mice6–9. WNTs are a family 77 
of 19 highly conserved morphogens capable of activating multiple signalling cascades. The 78 
most characterised one is the WNT beta-catenin-dependent pathway. The WNT/beta-catenin 79 
pathway (also known as canonical WNT pathway) is activated by the interaction of WNT 80 
ligands with Frizzled (FZDs) and Lipoprotein-related Protein Receptor 5 and 6 (LRP5/6) which 81 
leads to the intracellular accumulation of beta-catenin and its translocation to the nucleus. 82 
Within the nucleus, beta-catenin interacts with T-cell factor/lymphoid enhancer-binding factor 83 
(TCF/LEF) transcription factors promoting the transcription of target genes such as AXIN210. 84 
Other, so called “non-canonical” WNT pathways, are activated by the interaction of WNT 85 
ligands with FZDs and other co-receptors such as Receptor Tyrosine Kinase (RYK) and 86 
Retinoic Acid-Related Orphan Receptor (RORs), driving the activation of downstream 87 
signalling cascades activated by intracellular calcium release and/or associated with 88 
intercellular communication to coordinate polarity between adjacent cells11. 89 
Ca2+Calmodulin-dependent Kinase II (CaMKII) is an intracellular kinase that can be activated 90 
by several stimuli including WNTs12 and inflammatory stimuli13,14. CaMKII is a Ser/Thr kinase 91 
expressed in mammals in 4 isoforms, alpha, beta, gamma and delta15. Binding of 92 
Ca2+/Calmodulin to CaMKII transiently activates it. Once activated, CaMKII phosphorylates its 93 
substrates, including itself. The autophosphorylation of CaMKII in T287 results in its 94 
constitutive activation, even in the absence of further stimulation16. WNT-induced CaMKII 95 
activity regulates chondrocyte differentiation12. 96 
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We showed that a single WNT ligand could simultaneously activate the beta catenin-97 
dependent and the CaMKII-dependent WNT pathways with distinct biological outcomes12.  98 
These data suggest an important and still uncharacterised role for the WNT/CaMKII pathway 99 
in the maintenance of cartilage homeostasis. To test this hypothesis, the current study 100 
investigates the role of the WNT/CaMKII pathway in the context of osteoarthritis.  101 
Methods 102 
Patients 103 
Preserved (Mankin score ≤ 417) human articular cartilage samples were obtained from the 104 
femoral condyles removed during total knee replacement for osteoarthritis following informed 105 
consent (4 male and 2 female patients aged between 51 and 76). All procedures were 106 
approved by the East London and The City Research Ethics Committee 3 (ethics approval 107 
REC N. 07/Q0605/29). Full thickness explants were prepared for histology, and chondrocytes 108 
were isolated and expanded in-vitro as previously described12. Normal cartilage samples were 109 
retrieved from 3 patients (one 58 years-old, and two males aged respectively 14 and 16) 110 
undergone lower limb amputation because of malignant bone tumours. The samples were 111 
obtained upon favourable opinion of the Ethics Committee of the Ärztekammer Schleswig- 112 
Holstein, Bad Segeberg, Germany. We performed all procedures in accordance to relevant 113 
guidelines and regulations. 114 
 115 
Primary cells, cell lines and tissues 116 
Bovine chondrocytes were isolated from metatarsal joints obtained from a local abattoir within 117 
24 hours from death. Experiments were performed when primary chondrocytes reached 80% 118 
confluence (passage 0, P0) as previously described18. C3H/10T1/2 cells (ATCC) were cultured 119 
according to the manufacturer’s instructions.  120 
Murine femoral heads and patellae were explanted from 1 month-old male 129/Sv mice and 121 
processed for gene expression analysis (see below). 122 
If not differently indicated, cells were stimulated in complete medium (DMEM/F-12 1:1 plus 123 
GlutaMax, 10% FBS, 1 mM sodium pyruvate , and 2% antibiotic antimycotic solution 124 
ThermoFisher Scientific) supplemented with human recombinant WNT3A (100ng/ml; R&D), 125 
DKK1 (100ng/ml, R&D), IL1B (20ng/ml; InvivoGen), KN93 or its inactive control KN92 (10μM; 126 
EMD Millipore), Autocamtide-2 related inhibitory peptide II, AIP, 5μM; Calbiochem) or 127 
respective vehicles as indicated.  128 
 129 
siRNA preparation and transfection 130 
Small interfering RNA for mouse CAMKIIγ was prepared using the Silencer siRNA 131 
Construction Kit (Life Technologies) following manufacturer’s instructions. siCaMKIIγ S: 132 
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AAGGGTTTAAGGGTTTCACTACCTCGTGTCCTGTCTC; AS: 133 
AAACACGAAAACACGAGGTAGTGAAACCCCCTGTCTC; scramble siRNA, S: 134 
AATTCCGCAATTCCGCTCTGGACTGTAGTCCTGTCTC; AS: 135 
AAGAACTTAAGAACTTGATCAACCAGATGCCTGTCTC. The siRNA were used at 20nM and 136 
were transfected in C3H/10T1/2 cells using JetPRIME transfection reagent (Polyplus) as 137 
described in18.  138 
 139 
RNA isolation and quantitative real time PCR 140 
RNA isolation and PCR were performed as previously described12. For a complete list of 141 
primers and conditions refers to Supplementary Table 1.  142 
 143 
Microarray analysis: 144 
Total RNA was quantified using a Nanodrop™ ND-1000 Spectrophotometer and assessed for 145 
quality (QC) using the Agilent™ 2100 Bioanalyzer Pico kit. Five nanograms of total RNA with 146 
RNA integrity numbers (RINs) higher than 9 were selected for the microarray study. A Poly-A 147 
Spiking Control (Life Technologies) was used as amplification control. 148 
Single primer isothermal amplification (SPIA) technology was used to generate cDNA using 149 
NuGen Ovation Pico WTA System V2 kit, following manufacturer's instructions. The SPIA 150 
cDNA was subjected to QC, fragmented and Biotin-labelled using the NuGen Encore Biotin 151 
Module according to the manufacturer's instructions. The processed cDNA was subjected to 152 
a further round of QC to assess fragmentation size (Agilent 2100 Bioanalyzer Nano kit; 153 
fragment size < 200nt). 154 
Hybridization cocktails were prepared according to Nugen's recommendations for Human 155 
Gene 2.0 ST arrays and hybridization took place at 45°C for 16-20 hours in an Affymetrix 156 
Genechip Hybridization oven 645. 157 
The arrays were washed and stained using wash protocol FS450_0002 as recommended by 158 
Affymetrix on the GeneChip Fluidics station 450. The arrays were scanned using the 159 
Affymetrix GeneChip Scanner. CEL files were QC checked using the Expression Console 160 
software package (Affymetrix, Thermo Fisher) by using standard metrics and guidelines for 161 
the Affymetrix microarray system. Data were normalised together using the Robust Multi-array 162 
Average (RMA) sketch algorithm. 163 
The processing of all sample files was performed using R Programming Language (R). In 164 
brief, raw data was inputted using the 'read.celfiles' function of the 'oligo' R package19, with 165 
data then undergoing Robust Multiarray Average (RMA) normalisation using the 'rma' function. 166 
For cross-sample comparisons, the study design model was first created by identifying sample 167 





Immunohistochemical analysis 171 
CaMKII isoforms and phosphoCaMKII (pCaMKII) were detected by indirect 172 
immunofluorescence as described in12. For a list of retrieval methods, antibodies and dilutions 173 
please refer to Supplementary Table 2. All images were acquired using identical settings on 174 
an Olympus BX61 microscope and consistently modified for best rendering using Adobe 175 
Photoshop. The fluorescent and dapi images of the same field were superimposed, or the 176 
fluorescent and Nomarski images of the same field were inverted and superimposed 177 
(subtraction). 178 
 179 
Instability-induced OA in mice 180 
All animal procedures were approved by the UK Home Office (PPL 70-7986). All the 181 
experimental procedures were performed in accordance to relevant guidelines and 182 
regulations. Mice were kept in an approved animal care facility, were housed 4 or 5 per cage 183 
in standard cages and fed ad libitum. Ten week old, male C57BL/6 mice (Charles River) were 184 
subjected to resection of the medial collateral ligament and of the anterior horn of the medial 185 
meniscus (menisco-ligament injury – MLI) as previously described20. In each cage, the animals 186 
were randomized to receive either PBS or KN93 (see Supplementary Table 3). The 187 
contralateral knee underwent sham surgery (arthrotomy but no damage to ligaments or 188 
menisci). The joint capsule was sutured with Vicryl 6-0 and the skin with Ethylon 5-0 sutures 189 
with atraumatic needles (Ethicon).  190 
 191 
Pharmacological blockade of CaMKII 192 
Four weeks after surgery the mice were randomized to receive either the water-soluble version 193 
of the CaMKII inhibitor KN93 or PBS as control (15 animals per group). For the first 3 days 194 
KN93 (10µmol/Kg/day) or PBS were administered by intraperitoneal injection. Subsequently, 195 
ALZET® osmotic minipumps (Charles River Laboratories) were inserted subcutaneously on 196 
the back of the mice allowing a continuous release of KN93 (5µmol/Kg/day) or PBS for 197 
additional 28 days. The pumps were changed once during this time. The animals were then 198 
killed by cervical dislocation. 199 
 200 
Histology and OA scoring 201 
Knee joints were dissected, the majority of the soft tissue was removed, and the joints were 202 
fixed in 70% ethanol following which they were decalcified in formic acid, embedded in paraffin 203 
and sectioned as described in7. The sections were stained with Safranin O (SO) (0.1%, pH4). 204 
Images were taken using the same settings on an Olympus BX61 microscope and consistently 205 
modified for best rendering using GIMP software. The extent of cartilage degradation was 206 
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scored by two blinded, independent investigators using the Osteoarthritis Research Society 207 
International (OARSI) scoring system21. At least 5 sections/knee were scored. 208 
 209 
Histomorphometry 210 
Proteoglycan loss, osteophyte size and differentiation, and subchondral bone thickness were 211 
measured by histomorphometry using ImageJ22. The mean values from at least 3, but on 212 
average 5 sections from each knee (1 section every 50µm, spanning the entire depth of the 213 
joint) were calculated and used for statistical analysis. 214 
Proteoglycan loss was analysed by densitometry of the articular cartilage as previously 215 
described7. In brief, images were rotated so the cartilage-bone junction in the middle of the 216 
plateau was horizontal. This is important so that non‐cartilage staining in the bone marrow 217 
spaces can be eliminated. The tibial plateau was selected to include the growth plate, any 218 
osteophytes and up to the end of the cartilage; and selections from every section were placed 219 
on one canvas, so they were perfectly aligned horizontally. To isolate the metachromatic 220 
Safranin O staining from the background and most of the orthochromatic staining (subchondral 221 
bone), the RGB image was transformed into an HSB stack. On the ‘Saturation’ slice, a 222 
rectangle 600microns wide and the full height of the canvas was placed over the first section 223 
to include the tibial plateau, making sure to exclude any osteophytes and the “bulgy” part near 224 
the intercondylar notch. Ctrl+1 was pressed, and then the rectangle was moved laterally to the 225 
next section and Ctrl+2 was pressed. This was repeated until all sections were selected and 226 
then Ctrl+3 plotted the density profile of each section. The first peak is the articular cartilage. 227 
A horizontal line was drawn to cut residual background if any, and a lateral line to limit the 228 
articular cartilage peak and eliminate any staining of bone marrow spaces. Using the wand 229 
tool to select the inside of the density profile returned the area. These results were copied 230 
from the measurements box to a statistics programme for further analysis.  231 
Osteophytes consistently developed only on the medial tibial compartment of the operated 232 
joints. On individual sections, osteophyte size was determined by selecting the osteophyte 233 
with the polygon tool, and ensuring a global scale had been set, measuring the area. 234 
Osteophyte differentiation was assessed by comparing the intensity of SO staining with the 235 
staining of the growth plate, which was set as the threshold for comparison in Image J and 236 
defined as the staining for fully differentiated cartilage. The percentage of the thresholded area 237 
in each individual section was then normalised for the area of the osteophyte. The points in 238 
the graph represent the average of the measurements for multiple sections (at least 3/mouse).  239 
Subchondral bone thickness was determined by selecting the subchondral area underneath 240 





Micro-CT scanning 244 
Tibia were fixed in 70% ethanol and scanned with Skyscan 1174 Micro-CT scanner (Skyscan, 245 
Antwerp, Belgium) at 53kV, 785µA, 0.7° rotation and 12.57µM isometric voxel resolution. The 246 
individual slices were reconstructed using NRecon software (Skyscan) with an algorithm that 247 
included maximum ring artefact correction, 70% beam-hardening correction and misalignment 248 
compensation. 249 
 250 
Micro-CT analysis, Tibiae epiphyseal volume measurement 251 
The reconstructed scan was rotated and resliced using ImageJ22 in a coronal orientation. 252 
Using CTAn software (Skyscan), the tibial epiphysis was reconstructed as a volume of interest 253 
(VOI) by manually selecting the epiphysis on every 10th slice for the entire stack of images. A 254 
threshold of 90 density units was set to distinguish mineralised from non-mineralised tissue 255 
within the trabeculae.  256 
 257 
Statistical analysis 258 
Parametric data were compared with the t test or Anova with Tukey-Post test for multiple 259 
comparisons. When possible, data transformation was applied to satisfy the assumptions of 260 
parametric tests as described24. Non-parametric data were analysed using the Wilcoxon–261 
Mann–Whitney test. p Values <0.05 were considered significant: *p<0.05; **p<0.01; 262 
***p<0.001. For the analysis of the microarray experiment, individual comparisons within the 263 
study design model were conducted by fitting a linear model independently for each probe, 264 
with group as the y variable, using 'lmfit' ('limma' R package)25. The linear fit for each 265 
comparison was subsequently modified using the empirical Bayes ('eBayes') approach, which 266 
aims to bring the probe-wise variances across samples to common values, resulting in 267 
modified t-statistics, F-statistic, and log odds differential expression ratios. Finally, for each 268 
comparison, log2 fold-change (logFC), P value, and corrected P value (false discovery rate, 269 
FDR) was output. A cut-off of 10% FDR was used. Volcano plots were generated using 270 
`EnhancedVolcano` (`EnhancedVolcano` R package)26. 271 
 272 
Results: 273 
Transcriptional signature of the Wnt3a/CAMKII pathway in the articular chondrocytes  274 
We reported that WNT3A can activate both the Wnt/beta-catenin and the WNT/CaMKII 275 
pathways in articular chondrocytes with distinct, dose-dependent biological outcomes12. This 276 
implies that the modulation of some transcriptional targets of WNT3A will be due to activation 277 
of the WNT/beta-catenin-dependent pathway and others due to the activation of the CaMKII 278 
pathway. To elucidate the specific transcriptional signature of the CaMKII pathway activation 279 
by WNT3A, we performed an expression microarray analysis of human articular chondrocytes 280 
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treated with WNT3A in presence of KN93 or of its inactive control compound KN92 (Fig 1A-281 
C). We proposed that genes that are activated in a WNT/CaMKII-dependent manner will be 282 
upregulated by WNT3A, but only in the absence of the CaMKII inhibitor KN93. 283 
This analysis revealed that 44 genes were modulated by WNT3A in the absence of CAMKII 284 
inhibitor (Fig. 1D), but only 3 were modulated by WNT3A in a CaMKII-dependent manner 285 
(Fig1. D). The 3 genes modulated by WNT3A in a CaMKII-dependent manner included SRY-286 
Box Transcription Factor 9 (SOX9) (upregulated), the uncharacterized transcript RP11-287 
474G23.3 (downregulated) and Heme-Oxygenase 1 (HMOX-1) (downregulated) mRNA. The 288 
upregulation of SOX9 confirmed our previous results12. The downregulation of HMOX-1 mRNA 289 
in response to WNT/CaMKII activation was confirmed at qPCR level in human articular 290 
chondrocytes (Fig. 1E). Consistent with the requirement for CaMKII activation, KN93 291 
effectively rescued the downregulation of HMOX1 induced by WNT-3A and significantly 292 
upregulated its expression of this gene without exogenous WNT3A. 293 
We previously showed that the WNT/beta-catenin pathway antagonizes the WNT/CaMKII 294 
pathway in chondrocytes and that, therefore, its suppression using DKK1 results in hyper-295 
activation of the CaMKII-dependent targets12. In keeping with this model, treatment of 296 
chondrocytes with DKK1 alone decreased the expression of HMOX-1 (Fig. 1F) and did not 297 
rescue the downregulation of HMOX-1 induced by WNT3A, confirming that HMOX-1 is a 298 
negative target of the WNT3A/CaMKII pathway but not of the beta-catenin-dependent WNT 299 
pathway (Fig. 1F).  300 
Activated CaMKII and HMOX1 expression are inversely correlated in osteoarthritis. 301 
We next sought to confirm our in vitro findings in human cartilage and human OA pathology. 302 
We mined transcriptomics data in publicly available OA cartilage databases27. CaMKIIγ and –303 
δ RNA were the most expressed CaMKII isoforms at mRNA levels in normal as well as in 304 
osteoarthritic cartilage (Fig. 2C). A similar expression pattern was detected in a previously 305 
reported expression microarray in human cartilage explants6 (Fig. 2A) and in cultured human 306 
chondrocytes through in vitro culture (Fig.2B). Confirming a previous report28, CaMKII 307 
phosphorylation was increased in osteoarthritic cartilage as assessed with immunostaining 308 
with an antibody directed to the T287 residue (Fig. 2D). In keeping with our in vitro data 309 
showing that HMOX-1 is a negative CaMKII target, HMOX-1 expression decreased in cartilage 310 
isolated from OA patients (Fig. 2E). Although HMOX-1 expression can be modulated by 311 
several cell stressors, our  data suggest that the WNT/CaMKII pathway is activated in 312 
osteoarthritic cartilage. 313 
CaMKIIγ and –δ were the most expressed isoforms in cartilage isolated from murine femoral 314 
heads and patellae (Fig3. A-B), as previously seen in human cartilage. However, the different 315 
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CaMKII isoforms displayed a tissue specific-expression pattern in the murine joint. CaMKIIγ 316 
was expressed in the most superficial layer of the articular cartilage, with some limited 317 
expression in the menisci (Fig3. H-J). CaMKIIβ and –δ were also detectable in the surrounding 318 
soft tissues and in the bone marrow (Fig.3 C-G and K-O). To further validate a direct 319 
dependence of HMOX-1 downstream the activation of CaMKII, we silenced CaMKIIγ in the 320 
murine fibroblast cell line C3H/10T1/2 by siRNA (Fig 3P-Q). Silencing CaMKIIγ did not result 321 
in compensation from the other isoforms (Fig. 3P) and was sufficient to significantly upregulate 322 
HMOX-1 mRNA in these cells (Fig. 3Q). 323 
Pharmacological inhibition of CaMKII promotes cartilage degeneration and 324 
subchondral bone remodelling in a murine model of OA. 325 
To investigate if CaMKII inhibition affects the outcome of OA, we induced OA in adult mice by 326 
meniscus-ligament injury (MLI)20,29 and 4 weeks later we inhibited CaMKII by systemic 327 
administration of the CaMKII inhibitor KN93 or PBS as control for additional 4 weeks (Fig. 4A). 328 
The weight and general health status of the animals was monitored throughout the entire 329 
length of the stimulation and no significant difference between vehicle-treated vs inhibitor-330 
treated animals was noted (Supplementary Table 3).  CaMKII phosphorylation was effectively 331 
inhibited in KN93-treated animals (Supplementary Figure 1). Animals receiving KN93 332 
developed more severe OA, as quantified using the OARSI scoring system (Fig. 4B-C) and a 333 
corresponding decrease in proteoglycan content (Fig. 4 D and E), measured by 334 
histomorphometry. 335 
Bone changes were assessed by microCt. As expected, BV/TV of the entire tibial epiphysis 336 
increased in the MLI-operated compared to the sham-operated knee, but no difference was 337 
observed between treatment groups (Fig. 5A-B). Subchondral bone thickness, however, was 338 
significantly less increased in KN93-treated mice (Fig. 5C). Osteophyte size and bone vs 339 
cartilage ratio was not affected by KN93 treatment (Fig. 5C).  340 
CaMKII inhibition enhanced the capacity of IL1B to upregulate catabolic enzymes in 341 
articular chondrocytes.  342 
To gain insight into the mechanisms leading to increased cartilage degeneration in mice 343 
treated with KN93, we treated monolayer cultures of primary bovine articular chondrocytes 344 
with IL1B, a potent driver of extracellular matrix degradation (25). CaMKII inhibition with KN93 345 
(Fig. 6A, C, E, G) or AIP (Fig. 6B, D, F, H) induced the upregulation of the matrix-degrading 346 







Deregulation of Wnt signalling is associated with OA in in patients31 and in animal models8,9,32. 352 
We previously showed that WNT3A could simultaneously activate both the beta-catenin 353 
dependent and the CaMKII-dependent pathways in chondrocytes, resulting in distinct 354 
transcriptional and biological outcomes12. 355 
In this study we established the transcriptional signature of WNT/CaMKII signalling and 356 
identified HMOX-1 as a specific transcriptional target of this branch of the Wnt pathway (see 357 
schematic representation in Figure 7). We showed that CaMKII phosphorylation was 358 
increased in human and murine OA, while the expression of HMOX-1 was decreased. CaMKII 359 
blockade increased cartilage breakdown in an instability-induced OA model in mice. CaMKII 360 
inhibition increased the capacity of IL1B to upregulate catabolic enzymes in chondrocytes. 361 
The microarray analysis also confirmed  SOX9 mRNA upregulation in response to CaMKII 362 
blockade, as we previously showed by qPCR12. The mechanism by which CaMKII blockade 363 
results in SOX9 upregulation and, simultaneously, in upregulation of cartilage-degrading 364 
enzymes is unknown. It could be speculated that SOX9 upregulation occurs as a homeostatic 365 
response to the increased levels of extracellular matrix degradation. HMOX1 is a 366 
cytoprotective enzyme exerting antioxidant effects and chondroprotective effects in vitro33–35.  367 
The three CAMKII isoforms expressed in the joint had distinct expression patterns. CaMKIIγ 368 
was selectively expressed at the articular interface in the cartilage and in the menisci, while -369 
CaMKIIβ and CaMKIIδ had a broader expression pattern. Unfortunately, because of their high 370 
similarity across the phosphorylation site, no antibody specifically detecting the 371 
phosphorylated form of the different isoforms is available, making impossible to determine if 372 
only one isoform or all of them are activated in OA. Interestingly, however, we demonstrated 373 
that downregulation of CaMKIIγ alone is sufficient to mimic the effect of KN93 in inducing the 374 
upregulation of HMOX-1, suggesting that this isoform might be downstream the activation of 375 
the Wnt/CaMKII in the adult articular cartilage. The understanding of the differences in the 376 
activity of the four isoforms is going to be important for targeting CaMKII for therapeutic 377 
purposes. 378 
In our in vivo experiments, CaMKII inhibition affected subchondral bone thickness. During 379 
embryonic development CaMKII is a modulator of chondrocyte hypertrophic differentiation 380 
during development36,37 and therefore we cannot exclude that altered skeletal morphogenesis 381 
may have also contributed to the worsening of the chondropathy. 382 
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CaMKII appears to modulate the final outcomes of major homeostatic effects in cartilage 383 
homeostasis in a highly context-dependent manner both embryonic development and in 384 
adulthood12,28,36,37. Saitta et al. also recently reported that CaMKII blockade reduced the 385 
capacity of bone morphogenetic proteins (BMPs) to upregulate cartilage phenotypic 386 
markers38. Therefore, understanding the biology of CaMKII activation is going to be key to 387 
successfully harness such pathways in musculoskeletal medicine. 388 
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Figure legends 506 
 507 
Figure 1: HMOX1 is a selective target of the Wnt/CaMKII pathway in the articular 508 
chondrocytes. A-D. Human articular chondrocytes isolated from OA patients were treated 509 
with human recombinant WNT3A in presence of the CaMKII inhibitor KN93 or its inactive 510 
control molecule KN92. A. Volcano plot showing genes regulated by WNT3A (KN92+WNT3A 511 
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vs KN92), B. genes modulated by CaMKII inhibition in the presence of WNT3A 512 
(KN93+WNT3A vs KN92+WNT3A) and C. genes activated by WNT3A independently of 513 
CaMKII (KN93+WNT3A vs KN92). D. Venn diagram showing the number of significantly 514 
modulated genes in each group. E. qPCR confirming downregulation of HMOX-1 in response 515 
to WNT3A but not in the presence of the CaMKII inhibitor KN93. Microarray data were 516 
obtained by testing samples from 4 human donors. For 2 donors all conditions were tested in 517 
two independent cartilage explants; For one donor the condition KN92+WNT3A was tested in 518 
a single explant; for the remaining donor all the conditions were tested in a single explant per 519 
condition. F. qPCR showing that HMOX-1 is a selective target of the WNT/CAMKII branch and 520 
it is not modulated via activation of the WNT/beta-catenin pathway. n=3 human donors, 2 521 
technical replicates per donor. A-D. data were analysed with a linear models with 10% FDR p 522 
value correction. E-F. Data were analysed with one-way ANOVA followed by TukeyHSD post-523 
hoc test.  524 
Figure 2: CaMKII and HMOX1 expression are oppositely modulated in osteoarthritis. A. 525 
Relative expression of the four CaMKII mRNA isoforms as assessed by expression 526 
microarrays in human cartilage explants6. B. Gene expression analysis by semiquantitative 527 
PCR for CaMKIIα, -β, -γ, -δ, in P0 human articular chondrocytes (upper row). A pool of cDNA 528 
from brain, placenta and lymph node was used as positive control for the PCR (lower row) (n 529 
cycles= 40). All the samples were loaded and run in the same gel whose image was cut for 530 
best rendering. A picture of the full original gel can be found in Supplementary Figure 3. C. 531 
RNA expression of CaMKII isoforms in human cartilage retrieved from normal and OA human 532 
cartilage as assessed by Soul and colleagues in a previously performed RNAseq27 D. 533 
Immunodetection of phospho-CaMKII in normal and OA articular cartilage. Image 534 
representative of n=3. E. RNA deep sequencing analysis of HMOX-1 expression in normal 535 
and OA articular cartilage.  536 
Figure 3: Expression of CaMKII isoforms in murine cartilage. A-B. qPCR analysis of 537 
murine femoral heads and patellae removed from 1 month-old 129/Sv male mice (n=4). Gene 538 
expression was normalized for the housekeeping gene beta-actin. C-O. Immunofluorescence 539 
for CAMKII-β, -γ and δ in the murine joint. P. mRNA expression of the CaMKII isoforms after 540 
CAMKIIγ silencing by siRNA in C3H/10T1/2 cells. n=4. Q. Downregulation of CAMKII by 541 
siRNA was sufficient to upregulate HMOX-1 in C3H/10T1/2 cells n=4. Data analysed by t-test. 542 
F= femur; T=tibia; M=meniscus; BM=bone marrow; CL=cruciate ligament; SM=synovial 543 
membrane.  544 
Figure 4: Effect of CAMKII inhibition in vivo in a murine model of OA. A. Osteoarthritis 545 
was induced by removal of the anterior horn of the medial meniscus and transection of the 546 
17 
 
medial collateral ligament (MLI model). Four weeks after surgery, mice were administered 547 
KN93 (5uM) or PBS vehicle subcutaneously via a minipump for additional 4 weeks (the initial 548 
minipump was replaced after 2 weeks). The total volume administered over 4 weeks was equal 549 
to 400µl. n=15/treatment. B. Safranin O staining of representative sections of the medial 550 
compartment of the knee of mice treated with PBS or KN93. C. OARSI score of the medial 551 
and the lateral compartments of the MLI knees n=15/treatment D. Histomorphometry analysis 552 
of the MLI knees e. Correlation of the OARSI score and histomorphometry analysis. MF: 553 
medial femur; MT: medial tibia; LF: lateral femur; LT: lateral tibia. OARSI scores were analysed 554 
with Mann-Whitney test with Wilcoxon post-test. Histomorphometry data were analysed by t-555 
test. Linear regression was used to compare the OARSI scores and histomorphometry data.  556 
Figure 5: CaMKII inhibition decreases subchondral thickness. A-B. MicroCt analysis of 557 
operated and contralateral sham-operated knee joints of mice treated with KN93 or PBS 558 
vehicle upon surgical destabilization of the knee joint. A. Epiphyseal Bone volume / tissue 559 
volume of the entire tibial epiphysis of the operated knees. B. Comparison of the percent 560 
change of the BV/TV between the MLI and the sham operated knee in the two treatment 561 
groups. C. Histomorphometrical assessment of osteophyte area, % of cartilage area and 562 
histomorphometrical quantification of subchondral bone thickness. Data were analysed by t-563 
test. n=15/treatment. 564 
Figure 6: CaMKII inhibition enhanced the capacity of IL1B to upregulate catabolic 565 
enzymes in the articular chondrocytes: A-H. mRNA expression of ADAMTS4/5 and 566 
MMP3/13 measured by qPCR of bovine articular chondrocytes stimulated for 24h with IL1B 567 
(20ng/ml) in presence or absence of KN93 or its inactive analogue KN92 (both 10µM) (A, C, 568 
E, G) or in the presence or absence of the CAMKII inhibitor AIP (B, D, F, H) (5µM). Data were 569 
analysed with 2 ways ANOVA andTukey post-test. n=3 570 
Figure 7: Diagram summarising the transcriptional targets modulated by WNT3A in a CAMK2 571 
dependent manner and the effect of the pharmacological blockade of CAMK2 on the 572 
remodelling of joint tissues in osteoarthritis.  573 
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